Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Hershey, Pennsylvania 17033


Purpose:

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells. Interleukin-2 (IL-2) may stimulate the white blood cells to kill tumor cells. Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system and stop tumor cells from growing. Giving vaccine therapy with IL-2 may be a more effective treatment for Ewing's sarcoma or neuroblastoma. PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given with IL-2 in treating young patients with relapsed or refractory Ewing's sarcoma or neuroblastoma.


Study summary:

OBJECTIVES: - Determine the safety of vaccination comprising autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells followed by interleukin-2 (IL-2) in children with relapsed or refractory Ewing's sarcoma or neuroblastoma. - Determine antitumor immunity by examining cell phenotype and function in patients treated with this vaccine and cytotoxic T lymphocytes (CTL). - Determine the safety of CTL and IL-2 in these patients. OUTLINE: This is a pilot study. Tumor cells and blood cells are collected from patients and expanded in vitro. Tumor cells and Epstein-Barr virus-transformed B-lymphoblastoid cells (derived from blood cells) are fused together to produce the vaccine. - Vaccination: Patients receive vaccine comprising autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells subcutaneously (SC) once on days 0, 14, and 28 and interleukin-2 (IL-2) SC twice daily on days 1-7, 15-21, and 29-35. - Cytotoxic T lymphocytes (CTL): After vaccination, patients with evidence of antitumor immunity undergo leukapheresis to collect white blood cells for CTL expansion. Some of these patients then receive CTL IV once on days 0, 14, and 28 and IL-2 SC twice daily on days 1-7, 15-21, and 29-35. Patients are followed weekly for 2 weeks, every 2 weeks for 1 month, monthly for 3 months, and then every 2 months for up to 1 year post-vaccination. Patients who receive CTL are also followed annually for survival. PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 3 years.


Criteria:

DISEASE CHARACTERISTICS: - Diagnosis of Ewing's sarcoma OR neuroblastoma - Relapsed or refractory disease - Epstein-Barr virus positive PATIENT CHARACTERISTICS: Age - 1 to 30 Performance status - Lansky 70-100% OR - ECOG 0-2 Life expectancy - At least 8 weeks Hepatic - Bilirubin < 2.0 mg/dL - AST and ALT < 2.5 times normal (in the absence of liver metastases) - Patients without evidence of an obvious relationship between AST/ALT and disease activity are not eligible - Hepatitis B antigen and core antibody negative - Hepatitis C antibody negative Renal - Creatinine clearance > 50 mL/min Immunologic - HIV 1 and 2 negative - HTLV 1 and 2 negative Other - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception - No other moribund condition PRIOR CONCURRENT THERAPY: Biologic therapy - At least 3 months since prior autologous stem cell transplantation Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified


NCT ID:

NCT00101309


Primary Contact:

Study Chair
Kenneth G. Lucas, MD
Milton S. Hershey Medical Center


Backup Contact:

N/A


Location Contact:

Hershey, Pennsylvania 17033
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 15, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.